Live Breaking News & Updates on Neoadjuvant Breast Symphony Trial

Stay updated with breaking news from Neoadjuvant breast symphony trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Agendia, Inc.: Data Presented at the Miami Breast Cancer Conference Show MammaPrint and BluePrint Accurately Predict Pathologic Complete Response Rate Regardless of Age

(1)
Results support use of Agendia s genomic tests to better tailor pre-operative treatment and timing for surgery
Agendia, Inc., a world leader in precision oncology for breast cancer, announced new data from the prospective Neoadjuvant Breast Symphony Trial (NBRST) which demonstrate the predictive and prognostic abilities of MammaPrint
and BluePrint
, and underpin both assays pre-operative utility in pre-and post-menopausal patients. A poster highlighting these findings will be presented at the 38
th Annual Miami Breast Cancer Conference.
The poster, entitled
Pathologic Complete Response (pCR) Rates According to MammaPrint and BluePrint Results are Consistent Among Pre- and Post-Menopausal Patients,
outlines the first age-based analyses of MammaPrint and BluePrint assays in the pre-operative setting. As expected, the data show that pCR rates varied according to molecular subtype, with MammaPrint and BluePrint accurately predicting pCR in patie ....

United States , William Audeh , James Pellicane , Terri Clevenger , Bon Secours Cancer Institute , Agendia Inc , Neoadjuvant Breast Symphony Trial , Annual Miami Breast Cancer , Pathologic Complete Response , Rates According , Blueprint Results , Consistent Among , Post Menopausal Patients , Chief Medical Officer , Breast Oncology , ஒன்றுபட்டது மாநிலங்களில் , டெர்ரி கிளெவெஞ்சர் , பான் சேகௌுர்ச் புற்றுநோய் நிறுவனம் , ஆண்டு மியாமி மார்பக புற்றுநோய் , நோயியல் முழுமை பதில் , ரேட்ஸ் இசைய , வரைபடம் முடிவுகள் , போஸ்ட் மாதவிடாய் நின்றது நோயாளிகள் , தலைமை மருத்துவ அதிகாரி , மார்பக புற்றுநோயியல் ,

Agendia, Inc.: Agendia Spotlight Poster at SABCS 2020 Confirms Pre-Operative Utility of MammaPrint and BluePrint

Agendia, Inc.: Agendia Spotlight Poster at SABCS 2020 Confirms Pre-Operative Utility of MammaPrint and BluePrint
Clinical utility of molecular subtyping and risk of recurrence profiling highlighted in largest-ever data set evaluating genomic testing in neoadjuvant setting
First look at full 5-year NBRST trial outcome and survival data illustrate genomic diversity within all clinical subtypes of breast cancer
Agendia, Inc., a world leader in precision oncology for breast cancer, announced new 5-year data from the NBRST trial that will be presented in a poster spotlight discussion Thursday, December 10, 2020 from 3:30pm-4:45pm CST at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020).
The poster, entitled ....

United States , Pat Whitworth , Joyce Oshaughnessy , Terri Clevenger , James Pellicane , Bon Secours Cancer Institute , Agendia Inc , Nashville Breast Center , Breast Cancer Research Program For Texas Oncology , Us Oncology Network , Antonio Breast Cancer Symposium , Neoadjuvant Breast Symphony Trial , Nashville Breast , Blueprint Basal Type , Joyceo Shaughnessy , Breast Cancer Research Program , Texas Oncology , Luminala Type , Luminalb Type , Breast Oncology , ஒன்றுபட்டது மாநிலங்களில் , பேட் விட்வொர்த் , மகிழ்ச்சி ஓஷ்ௌஊக்னெஸ்ஸி , டெர்ரி கிளெவெஞ்சர் , பான் சேகௌுர்ச் புற்றுநோய் நிறுவனம் , நாஷ்வில்லி மார்பக மையம் ,